Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

ADMA Biologics Inc (ADMA) USD0.0001

Sell:$1.98 Buy:$1.99 Change: $0.015 (0.76%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
Sell:$1.98
Buy:$1.99
Change: $0.015 (0.76%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
Sell:$1.98
Buy:$1.99
Change: $0.015 (0.76%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Contact details

Address:
C/O Adma Biologics
Inc., 465 State Route 17
RAMSEY
07446
United States
Telephone:
+1 (201) 4785552
Website:
https://www.admabiologics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ADMA
ISIN:
US0008991046
Market cap:
$188.15 million
Shares in issue:
94.55 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Steven Elms
    Independent Chairman of the Board
  • Adam Grossman
    President, Chief Executive Officer, Co-Founder, Director
  • Jerrold Grossman
    Vice Chairman of the Board, Co-Founder
  • Brian Lenz
    Chief Financial Officer, Executive Vice President
  • James Mond
    Executive Vice President, Chief Scientific Officer, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.